Premium
Insights from compassionate use of tocilizumab for COVID‐19 to inform appropriate design of randomised controlled trials
Author(s) -
Baker Emma H.,
Patel Kamal,
Ball Jonathan,
Edwards Sarah,
Harrison Thomas S.,
Kaul Arvind,
Koh Mickey,
Krishna Sanjeev,
Leaver Susannah,
Kumar Vinodh,
Forton Daniel M.
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14466
Subject(s) - tocilizumab , medicine , cytokine release syndrome , ritonavir , clinical trial , immune dysregulation , immunology , cytokine , rheumatoid arthritis , immune system , viral load , t cell , chimeric antigen receptor , human immunodeficiency virus (hiv) , antiretroviral therapy